Rosetta Genomics Ltd. - Ordinar ROSG
0.43 0.00 (+0.00%)
At closeJun 28, 2019, 6:07 PM EDT
0.42 Day range 0.44
0.23 52-week range 2.82
- YTD
- -100.00%
- 1 year
- -100.00%
Analyst view
Consensus: buy
Buy
Price target (mean) 24.00
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -2.40 | 0.0% | 3.70M | +42.1% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -1.92 | 0.0% | 4.00M | +65.8% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 12.91M | +39.8% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 18.10M | +40.2% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2017 | Barrington Research | Downgrade | Outperform | Market Perform |
| Jan 7, 2016 | Aegis Capital | Initiated | — | Buy |
| Apr 29, 2015 | Barrington Research | Initiated | — | Outperform |
| Apr 16, 2015 | Cantor Fitzgerald | Upgrade | — | Buy |
| Jun 3, 2014 | Barrington Research | Initiated | — | Outperform |
| Oct 29, 2013 | Aegis Capital | Downgrade | — | Hold |
| Apr 11, 2013 | Sidoti & Co. | Downgrade | — | Neutral |
| Aug 22, 2012 | Aegis Capital | Initiated | — | Buy |